Nirantan Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 26 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.70 M
- Revenue Growth %
- Profit Growth -1100.00%
- Ebitda
- Net Worth -0.30%
- Total Assets %
About Nirantan Biotech
Nirantan Biotech Private Limited (NBPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 April 1998 and has a history of 26 years and nine months. Its registered office is in Pune, Maharashtra, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.70 M.
Nutan Desai and Suhasini Mandlekar serve as directors at the Company.
Company Details
-
Location
Pune, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24119MH1998PTC114440
-
Company No.
114440
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Apr 1998
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Nirantan Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Suhasini Mandlekar
|
Director | 11-Jul-2015 | Current |
|
Nutan Desai
|
Director | 13-Apr-1998 | Current |
Financial Performance of Nirantan Biotech.
Nirantan Biotech Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a substantial fall in profitability, with a 1100% decrease in profit. The company's net worth dipped by a decrease of 0.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nirantan Biotech?
In 2020, Nirantan Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹1.70 M
₹0
Charges Breakdown by Lending Institutions
- Bank Of Maharashtra : 0.15 Cr
- Janata Bahakari Bank Ltd. : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 May 2001 | Bank Of Maharashtra | ₹1.50 M | Open |
| 30 Mar 2000 | Janata Bahakari Bank Ltd. | ₹0.20 M | Open |
How Many Employees Work at Nirantan Biotech?
Unlock and access historical data on people associated with Nirantan Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nirantan Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nirantan Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
